Who is sponsoring NCT00030121?

NCT00030121 is sponsored by Suntory Pharmaceutical.

What drugs are being tested in NCT00030121?

Interventions in NCT00030121: recombinant human atrial natriuretic polypeptide.

What condition does NCT00030121 study?

NCT00030121 studies Respiratory Distress Syndrome.

Is NCT00030121 still recruiting?

NCT00030121 is currently completed. Last updated 19 February 2008.

Last reviewed 2008-02-19 · How we verify

NCT00030121

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Evaluation of the Safety and Efficacy of Carperitide Infusion in Patients With ARDS

Completed Phase 2 Last updated 19 February 2008

What this trial tests

Phase 2 trial testing recombinant human atrial natriuretic polypeptide in Respiratory Distress Syndrome. Completed.

Timeline

1 December 1999

Quick facts

Lead sponsor	Suntory Pharmaceutical
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Start date	1 December 1999

Drugs / interventions tested

recombinant human atrial natriuretic polypeptide — full drug profile →

Conditions studied

Respiratory Distress Syndrome — all drugs for Respiratory Distress Syndrome →

Sponsor

Suntory Pharmaceutical — full company profile →

Who can join

18 and older, any sex, with Respiratory Distress Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to determine whether Carperitide is safe and effective in the management of Acute Respiratory Distress Syndrome (ARDS).

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

What every intensivist should know about acute respiratory distress syndrome and diffuse alveolar damage.
Rios F, Iscar T, Cardinal-Fernández P. · · 2017 · cited 17× · PMID 28977098 · DOI 10.5935/0103-507x.20170044
Do Nonventilatory Strategies for Acute Lung Injury and ARDS Work?
· 2010

Verify or expand the search:

Other recruiting trials for Respiratory Distress Syndrome

Currently open trials in the same condition.

NCT07437391 — Effect of L-Carnitine Supplementation in Preterm Neonates · NA · recruiting
NCT06807983 — LUng and Cardiac Ultrasound for REspiratory Distress in ElDerly · NA · recruiting
NCT07154134 — Endocan and Copeptin Serum Levels in Preterm Neonates With Respiratory Distress Syndrome · recruiting
NCT06684379 — Study on Safety and Efficacy of Two Doses of PRS CK STORM in the Modulation of the Cytokine Storm for the Treatment of A · Phase 1, PHASE2 · recruiting
NCT06430554 — Personalized Ventilation Based on Ventilation-perfusion Mismatch and Lung Recruitability · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00030121 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Suntory Pharmaceutical
Last refreshed: 19 February 2008

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00030121.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing